Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-551-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$74.91 million
Profitability
Miscellaneous
Employees1,065
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($2.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.06) by $0.04. The biopharmaceutical company had revenue of $38.20 million for the quarter, compared to analysts' expectations of $42.24 million. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. Alnylam Pharmaceuticals's quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.61) earnings per share. View Alnylam Pharmaceuticals' Earnings History.
When is Alnylam Pharmaceuticals' next earnings date?
What price target have analysts set for ALNY?
16 analysts have issued twelve-month price targets for Alnylam Pharmaceuticals' stock. Their forecasts range from $70.00 to $198.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $121.1250 in the next twelve months. This suggests a possible upside of 47.9% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.
What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.
What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alnylam earnings and revenues beat estimates in the first quarter of 2019, owing to robust Onpattro sales. The company demonstrated good progress in global commercialization of Onpattro, continued success in R&D efforts with positive phase III results for givosiran, and a strong commitment to future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro in patients with cardiomyopathy. The company also expects to submit two NDAs (givosiran and inclisiran) in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, currently it depends heavily on Onpattro for growth, which is a concern. The company is heavily dependent on its partnerships for supporting operations and pipeline development activities. Shares of the company have outperformed the industry year to date." (5/8/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019)
- 3. Needham & Company LLC analysts commented, "Alnylam is expected to announce results of an interim analysis of the Phase 3 trial of givosiran in Acute Hepatic Porphyrias (AHP) later this month. The FDA has reportedly indicated that a statistically significant reduction in biomarker urine ALA level w/ the first 30 enrolled patients may be sufficient for accelerated approval. We expect a positive outcome based on strength of data collected from Phase 1/2 testing, in which profound and durable reductions in urine ALA levels were observed. Mgmt has guided for NDA submission by YE18. We assume U.S. commercial launch in 2H19 and WW peak sales $600-700M. Reiterate BUY." (9/13/2018)
Has Alnylam Pharmaceuticals been receiving favorable news coverage?
Headlines about ALNY stock have been trending positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Alnylam Pharmaceuticals.
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Commonwealth Bank of Australia (CSLLY), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TAK), GRIFOLS S A/S (GRFS), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS) and Mylan (MYL).
What other stocks do shareholders of Alnylam Pharmaceuticals own?
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
- Mr. Barry E. Greene, Pres (Age 56)
- Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
- Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
- Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)
Who are Alnylam Pharmaceuticals' major shareholders?
Alnylam Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.38%), BlackRock Inc. (5.88%), BlackRock Inc. (5.88%), Baillie Gifford & Co. (5.83%), Maverick Capital Ltd. (3.81%) and Price T Rowe Associates Inc. MD (3.15%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Which major investors are selling Alnylam Pharmaceuticals stock?
ALNY stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Eaton Vance Management, Tobam, Sofinnova Investments Inc., Pictet Asset Management Ltd., Pictet Asset Management Ltd., California Public Employees Retirement System and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include John Maraganore, Philip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Which major investors are buying Alnylam Pharmaceuticals stock?
ALNY stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Vanguard Group Inc., Farallon Capital Management LLC, Baillie Gifford & Co., Point72 Asset Management L.P., Nuveen Asset Management LLC, Invesco Ltd. and Marshall Wace LLP. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy shares of Alnylam Pharmaceuticals?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of ALNY stock can currently be purchased for approximately $81.89.
How big of a company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a market capitalization of $9.11 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.
What is Alnylam Pharmaceuticals' official website?
How can I contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]
MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
